ANRO
Alto Neuroscience, Inc.17.10
+0.07+0.41%
Dec 16, 4:00:02 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
531.23MP/E (TTM)
-Basic EPS (TTM)
-2.30Dividend Yield
0%Recent Filings
10-Q
8-K
8-K
Alto raises $50M for depression drug
Alto Neuroscience secured $50 million in a private placement on October 19, 2025, issuing 3.8 million common shares at $5.914 each and pre-funded warrants for 4.6 million more shares, led by Perceptive Advisors. This influx, timed after a positive FDA meeting, accelerates ALTO-207's development for treatment-resistant depression, targeting a Phase 2b trial by mid-2026 and Phase 3 by early 2027. Cash now lasts into 2028. Yet dilution looms for shareholders.
8-K
Pipeline expansion and board addition
Alto Neuroscience bolstered its precision psychiatry pipeline by acquiring ALTO-207, a dopamine agonist combo for treatment-resistant depression, backed by Phase 2a data showing significant MADRS score improvements (Cohen's d=1.1) and PAX-D study results. The company appointed Raymond Sanchez, M.D., a life sciences veteran, to its board on August 12, 2025, expanding expertise amid ongoing trials for ALTO-101 in schizophrenia and ALTO-300 in MDD. Cash stands at $148.1 million, funding operations into 2028; yet net loss widened to $17.7 million for Q2 2025. Board refresh sharpens strategic focus.
10-Q
Q2 FY2025 results
Alto Neuroscience posted a Q2 net loss of $17.7M, up 10.5% y/y from $16.0M, driven by steady R&D spend of $13.1M amid ALTO-100's MDD trial wrap and ALTO-300's enrollment pace, while G&A climbed 7.7% to $5.6M on personnel costs. YTD through June 30, 2025, net loss widened to $32.9M from $29.4M y/y, with operating cash burn at $30.3M versus $22.7M last year, reflecting milestone timing and headcount growth. Cash dipped to $147.6M from $168.2M year-end, bolstered by a $20M term loan draw (maturing 2029 at ~13% effective rate) and $2M Wellcome grant, yielding free cash flow of -$30.4M YTD (derived). In May, Alto closed the Chase acquisition for $3M upfront (cash mix), adding ALTO-207 and ALTO-208 with $71.5M contingent milestones tied to TRD and PD progress. Pipeline advances steadily. Yet securities litigation shadows investor confidence.
IPO
Employees
Sector
Industry
ALZN
Alzamend Neuro, Inc.
2.16+0.05
ANVS
Annovis Bio, Inc.
3.93+0.15
ATAI
Atai Beckley N.V
4.23+0.09
ATHE
Alterity Therapeutics Limited
3.07+0.06
CYBN
Cybin Inc.
6.66+0.00
CYTOF
Altamira Therapeutics Ltd.
0.07+0.00
KLTO
Klotho Neurosciences, Inc.
0.39+0.01
LBRX
LB Pharmaceuticals Inc
19.82-0.04
MNMD
Mind Medicine (MindMed) Inc.
12.26+0.18
NMRA
Neumora Therapeutics, Inc.
1.85-0.11